Nutraceutical Bio-Hemp, Inc., is pleased to announce the appointment of Dr. Levan Darjania as its new Strategic Adviser (R&D, Regulatios).

San Diego (02/15/2020) – Nutraceutical Bio-Hemp, Inc., is pleased to announce the appointment of Dr. Levan Darjania as its new Strategic Adviser (R&D, Regulatios).

Dr. Darjania will bring extensive knowledge of drug discovery and development, advanced formulation, bioanalysis, and pharmacokinetics to the Nutraceutical Bio-Hemp, Inc. to strengthen the product innovation and value chains while ensuring proper compliance with US FDA and USDA regulations. Dr. Darjania aims to bridge the learning gap for Nutraceutical Bio-Hemp, Inc., quality control, advanced formulation programs, and product development, especially in future dietary supplement and beverage markets. In addition, he will provide advanced expertise in scientific asset development for the international distribution of Nutraceutical Bio-Hemp, Inc. products.

Dr. Darjania is an accomplished R&D professional and program manager with over 26-years’ experience in biotechnology, pharmaceutical drug development (both industry and academia) and proven track record of success in developing and directing in-house and collaborative R&D programs, and forward-thinking strategic planning capabilities. His research interests include preclinical and clinical R&D, ADME, drug formulation and delivery, pharmacokinetics, toxico-kinetics and bioanalysis, cGLP-IND-enabling studies (Modules 4, 2) for FDA filing. Dr. Darjania is a lead author or co-author of numerous research articles in peer-reviewed journals and presenter or co-presenter at numerous professional conferences and meetings in the U.S. and internationally. Dr. Darjania is also experienced with working with Private Investment Groups to oversee the Global Project Analysis, R&D activities, due diligence process, and scientific communications.

Dr. Darjania will be involved in spearheading the second generation of cannabinoid based supplements, where the major cannabinoids as well as minor cannabinoids and other hemp derived bioactive substances will be evaluated in various preclinical and clinical studies in the effort to increase the systemic exposure/delivery and overall wellness beneficial efficacy. His mission is to put cannabinoids through preclinical and clinical studies in the collaboration with academia and medical entities (nationally and internationally) in order to prove scientifically that those substances can be an effective add-on medical treatment in conjunction with other compounds.